Peptides for Weight Loss

6 research peptides are currently studied for weight loss. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.

GLP-1 (Glucagon-Like Peptide-1) is a 30-amino acid incretin hormone produced by intestinal L-cells in response to nutrient intake. This peptide plays a pivotal role in glucose metabolism and appetite regulation. Notably, GLP-1 receptor agonists, such as semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda), have revolutionized the treatment landscape for type 2 diabetes and obesity. These analogs are designed to resist degradation by DPP-4 enzymes, extending their half-life from mere minutes to several hours. Clinical trials have demonstrated significant weight loss outcomes associated with GLP-1 receptor activation, with reductions in body weight often exceeding 10% in some patient populations. This evidence underscores the therapeutic potential of GLP-1-based interventions, although considerations regarding gastrointestinal side effects and individual variability in response remain pertinent.

Peptide YY (PYY) is a 36-amino-acid gut hormone released from L-cells in the ileum and colon postprandially. The predominant form, PYY3-36, interacts with Y2 receptors in the hypothalamus, effectively reducing appetite. Numerous human infusion studies have consistently highlighted PYY's ability to decrease caloric intake by approximately 30%, particularly in lean individuals. However, research indicates that obese individuals often exhibit lower postprandial PYY levels, which may contribute to dysregulated appetite control. While the potential of PYY as a therapeutic target is clear, challenges such as dose-related nausea have complicated its clinical development. Future research may focus on optimizing delivery methods or developing analogs that enhance its appetite-suppressing effects while minimizing adverse reactions.

Tesofensine is a triple monoamine reuptake inhibitor that has garnered attention for its weight loss properties, despite its original development for neurological conditions such as Alzheimer's and Parkinson's disease. Phase II clinical trials have shown promising results, with participants achieving an average weight loss of approximately 10% over 24 weeks. Its mechanism involves the modulation of serotonin, norepinephrine, and dopamine, which collectively contribute to appetite suppression and enhanced energy expenditure. Although not a peptide, tesofensine is often discussed in conjunction with peptide therapies due to its significant weight loss efficacy. The ongoing Phase III trials, licensed to Saniona, aim to further elucidate its safety and effectiveness in diverse populations, while also addressing potential side effects associated with monoamine reuptake inhibition.

Amycretin represents a novel approach in obesity treatment as a unimolecular peptide co-agonist, engaging both GLP-1 and amylin receptors. Developed by Novo Nordisk, this compound is primarily being investigated in an oral formulation, which is a significant advancement given the traditional delivery methods for peptide therapies. In the Phase 2 REDEFINE 1 trial, amycretin demonstrated an impressive potential for weight loss, achieving up to 13.1% reduction in body weight over 36 weeks. This dual receptor activation is thought to enhance satiety and metabolic regulation synergistically. While the evidence from early clinical trials is encouraging, further research, including anticipated Phase 3 trials starting in 2026, will be crucial to confirm its efficacy and safety profile in broader populations.

Neuromedin U (NMU) is a neuropeptide with roles in regulating appetite, energy expenditure, and stress responses. Initially isolated from porcine spinal cord, NMU functions through two G-protein-coupled receptors, NMUR1 and NMUR2, which mediate its effects on appetite and metabolism. Preclinical studies have demonstrated NMU's potent anorexigenic properties, with central administration resulting in significant reductions in food intake compared to other appetite-suppressing peptides. Despite its promising preclinical profile, the transition to clinical applications is still in the early stages, and further research is needed to explore NMU's potential as a therapeutic target for obesity, as well as the mechanisms underlying its effects on energy balance.

BAM-15 is classified as a mitochondrial protonophore, a compound that facilitates the uncoupling of oxidative phosphorylation, leading to the dissipation of the proton gradient across the inner mitochondrial membrane. This mechanism results in the conversion of stored energy into heat rather than adenosine triphosphate (ATP), distinguishing BAM-15 from traditional uncouplers like 2,4-dinitrophenol (DNP), which have been associated with significant safety concerns. Preclinical studies have demonstrated that BAM-15 can effectively reduce body fat without decreasing food intake, lean muscle mass, or core body temperature, while also enhancing insulin sensitivity. Although BAM-15 is not a peptide, its inclusion in discussions surrounding peptide-based metabolic therapies is warranted due to its potential implications for weight management. However, the evidence is primarily derived from animal models, and further research is necessary to establish its efficacy and safety in human subjects.